H. Bays
Physiology · 2003–2019
A researcher in the Science corpus: 7 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.
Subfields
- Physiology — 52 citations into it; #1,741 of 2,276 by trust here, #1,813 by citations
Whom H. Bays trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts H. Bays overall
Papers from H. Bays's perspective
Ordered by how strongly the researchers H. Bays trusts endorse each paper. Same corpus, a different order for every researcher.
- The hormone resistin links obesity to diabetes (Nature)
- Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. (Arteriosclerosis, Thrombosis and Vascular Biology)
- Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Ikkβ (Science)
- Prevention of fat-induced insulin resistance by salicylate. (Journal of Clinical Investigation)
- Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. (Journal of Clinical Endocrinology and Metabolism)
- Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. (Diabetes Care)
- C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. (Journal of the American Medical Association (JAMA))
- The PPARs: from orphan receptors to drug discovery. (Journal of Medicinal Chemistry)
- Lipotoxic diseases. (Annual Review of Medicine)
- Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus. (American Journal of Clinical Nutrition)
Their papers
- Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. (2004) — 683 citations
- National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. (2015) — 718 citations
- Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol (2019) — 630 citations
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. (2018) — 1,439 citations
- National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. (2015) — 716 citations
- Multicenter, placebo-controlled trial of lorcaserin for weight management. (2010) — 873 citations
- Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). (2003) — 1,304 citations